Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$35.24 USD

35.24
783,779

-0.32 (-0.90%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $35.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TNDM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Tandem Diabetes Care, Inc. [TNDM]

Reports for Purchase

Showing records 121 - 140 ( 239 total )

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 121

04/27/2017

Daily Note

Pages: 3

Discontinuation of Research Coverage

Provider: Feltl & Company

Price: 10.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 122

04/17/2017

Daily Note

Pages: 41

1Q17 Preview: Outperforming in MedTech Year-to-Date Reflects Stable Fundamentals That Should Continue Throughout 2017

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 123

03/30/2017

Company Report

Pages: 12

Best-In-Class Insulin Pump Portfolio, Upcoming Inflection Point in Sales Growth, and Attractive Valuation; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 124

03/09/2017

Company Report

Pages: 9

Q4 inline, secondary coming, but pipeline on track - reiterate BUY, target to $4.50

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 125

02/27/2017

Company Report

Pages: 7

Insulin Pump Project: Historical survey of ~7,000 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 126

01/24/2017

Industry Report

Pages: 6

Medical Devices: Diabetes Market Implications from JNJ''s Potential Exit

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 127

01/13/2017

Industry Report

Pages: 6

CMS to Reimburse DXCM''s G5; Positive for DXCM, PODD, TNDM; Negative for MDT

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 128

11/02/2016

Company Report

Pages: 9

Q3 misses estimates, confusion in marketplace, lower to BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 129

11/02/2016

Company Report

Pages: 8

3Q16 Disappoints, But We Continue To View Tandem''s Insulin Pump Technology As Best-in-Class; Reducing PT to $11; Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 130

11/01/2016

Company Report

Pages: 8

Insulin Pump Project: Historical survey of ~6,700 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 131

10/18/2016

Industry Report

Pages: 5

Highlights from JNJ''s 3Q16 Results Bode Well for the MedTech Sector; Most Positive Read

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 132

10/17/2016

Daily Note

Pages: 39

3Q16 Preview: Stable Growth Trends Through The End of 2016

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 133

09/29/2016

Industry Report

Pages: 6

670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 134

09/29/2016

Industry Report

Pages: 6

670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 135

09/05/2016

Industry Report

Pages: 10

Diabetes Technology Panel Highlights The Opportunities That Lie Ahead

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 136

08/17/2016

Industry Report

Pages: 17

Medical Devices - Day 1: Key Takeaways from the PacGrow Healthcare Conference

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 137

08/17/2016

Industry Report

Pages: 23

Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 138

07/29/2016

Company Report

Pages: 9

Q2 roughly inline -t:slim X2 a master stroke - reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 139

07/29/2016

Company Report

Pages: 9

Strong Underlying Growth - New Insulin Pump Platform Suggest More Share Gains To Come; Reiterate OP

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Tandem Diabetes Care, Inc.

Industry: Medical - Instruments

Record: 140

07/28/2016

Company Report

Pages: 8

Insulin Pump Project: Historical analysis of ~6,500 users

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party